<SEC-DOCUMENT>0001387131-18-005012.txt : 20180927
<SEC-HEADER>0001387131-18-005012.hdr.sgml : 20180927
<ACCEPTANCE-DATETIME>20180927160514
ACCESSION NUMBER:		0001387131-18-005012
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180927
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180927
DATE AS OF CHANGE:		20180927

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		181091052

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_092718.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 14.3pt; text-align: center"><FONT STYLE="font-size: 12pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>FORM 8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 14.3pt; text-align: center">Date of Report (Date of earliest event
reported): September 27, 2018&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>TherapeuticsMD,
    Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.5pt; padding-left: 5.5pt; text-align: center"><FONT STYLE="font-size: 10pt">(Exact Name of Registrant as Specified in its Charter)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-00100</B></FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or Other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Jurisdiction of Incorporation)</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">6800 Broken Sound Parkway NW, Third Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Boca Raton, FL 33487</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Office) (Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant's telephone number, including area
code: (561) 961-1900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 14.3pt; text-align: justify">Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9744;&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9744;&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.3pt; text-align: justify; text-indent: -14.3pt">&#9744;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.3pt; text-align: justify; text-indent: -14.3pt">&#9744;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230-405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Emerging growth company &#9744;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. &#9744;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif"><B>Item 7.01</B></TD>
    <TD STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif"><B>Regulation FD Disclosure.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 11pt; text-align: justify; text-indent: 27.5pt">On September 27,
2018, TherapeuticsMD, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), issued a press release announcing that the
Company has entered into discussions with the U.S. Food and Drug Administration (FDA) regarding the proposed label for TX-001HR,
the Company&rsquo;s investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel
for the treatment of moderate-to-severe vasomotor symptoms due to menopause. A copy of the press release is furnished as Exhibit&nbsp;99.1
to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference. The information included in this Item 7.01
and in Exhibit 99.1 shall not be deemed &ldquo;filed&rdquo; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934,
as amended (the &ldquo; <U>Exchange Act</U> &rdquo;), or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such a filing.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif"><B>Item 9.01</B></TD>
    <TD STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif"><B>Financial Statements and Exhibits.</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="width: 7%; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Exhibits</I></FONT></TD>
    <TD STYLE="width: 86%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Exhibit</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><U>Number</U></FONT></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="ex99-1.htm">99.1</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Press Release from TherapeuticsMD, Inc., dated September 27, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12.1pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;September 27, 2018</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">THERAPEUTICSMD, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ <I>Daniel A. Cartwright</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Daniel A. Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-8k_092718.htm">TherapeuticsMD, Inc. 8-K</A></P>

<P STYLE="margin: 0; text-align: right">Exhibit 99.1&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FOR
IMMEDIATE RELEASE</B></FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TherapeuticsMD
Enters Into Label Discussions for TX-001HR</B></FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOCA
RATON, Fla.&mdash;September 27, 2018&mdash;</B> TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women&rsquo;s healthcare company,
today announced that the Company has entered into discussions with the U.S. Food and Drug Administration (FDA) regarding the proposed
label for TX-001HR, the Company&rsquo;s investigational bio-identical hormone therapy combination of estradiol and progesterone
in a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause. As previously announced,
the Prescription Drug User Fee Act (PDUFA) target action date for the completion of the FDA&rsquo;s review of the new drug application
(NDA) for TX-001HR is October 28, 2018. The Company does not anticipate providing subsequent updates with respect to label discussions
prior to the PDUFA target action date. There can be no assurance that the FDA will approve the NDA for TX-001HR, or that such
approval will occur by the PDUFA target action date, and the entrance into label discussions does not imply otherwise.</FONT></P>

<P STYLE="font: 10pt/normal Arial, Helvetica, Sans-Serif; margin: 0 0 9.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About&nbsp;TherapeuticsMD,
Inc.</B></FONT></P>

<P STYLE="font: 10pt/normal Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
Inc.&nbsp;is an innovative healthcare company focused on developing and commercializing novel products exclusively for women.
Our products are designed to <FONT STYLE="background-color: white">address the unique changes and challenges women experience
through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management</FONT>.
The company is c<FONT STYLE="background-color: white">ommitted to advancing the health of women and championing awareness of their
healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD
and on Facebook: TherapeuticsMD.</FONT></FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt/normal Arial, Helvetica, Sans-Serif; margin: 0 0 9.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements </B></FONT></P>

<P STYLE="font: 10pt/normal Arial, Helvetica, Sans-Serif; margin: 0 0 9.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release by&nbsp;TherapeuticsMD, Inc.&nbsp;may contain forward-looking statements. Forward-looking statements may include,
but are not limited to, statements relating to TherapeuticsMD&rsquo;s objectives, plans and strategies as well as statements,
other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes
or anticipates will or may occur in the future. These statements are often characterized by terminology such as &ldquo;believes,&rdquo;
&ldquo;hopes,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;should,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo;
&ldquo;will,&rdquo; &ldquo;expects,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;positioned,&rdquo; &ldquo;strategy&rdquo;
and similar expressions and are based on assumptions and assessments made in light of management&rsquo;s experience and perception
of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are
not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company&rsquo;s
control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking
statements are described in the sections titled &ldquo;Risk Factors&rdquo; in the company&rsquo;s filings with the&nbsp;Securities
and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports
on Form 8-K, and include the following: whether the FDA will approve the NDA for the company&rsquo;s TX-001HR product candidate
and whether such approval will occur by the PDUFA target action date; the company&rsquo;s ability to maintain or increase sales
of its products; the company&rsquo;s ability to develop and commercialize IMVEXXY<SUP>TM</SUP>, ANNOVERA and its hormone therapy
drug candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants
and conditions under its term loan agreement; the length, cost and uncertain results of the company&rsquo;s clinical trials; the
potential of adverse side effects or other safety risks that could preclude the approval of the company&rsquo;s hormone therapy
drug candidates or adversely affect the commercialization of the company&rsquo;s current or future approved products; the company&rsquo;s
reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement
from government authorities and health insurance companies for the company&rsquo;s products; the impact of product liability lawsuits;
the influence of extensive and costly government regulation; the volatility of the trading price of the company&rsquo;s common
stock and the concentration of power in its stock ownership. PDF copies of the company&rsquo;s historical press releases and financial
tables can be viewed and downloaded at its website:&nbsp;www.therapeuticsmd.com/pressreleases.aspx.</FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTACT</B></FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact</B></FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nichol
Ochsner,</FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
President Investor Relations</FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">561-961-1900,
ext. 2088</FONT></P>

<P STYLE="font: 10pt/107% Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nochsner@TherapeuticsMD.com</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%; border-bottom: Black 1pt solid"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $-U<W1O;65R
M(%-E<G9I8V4    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,U
M-0  DI(  @    ,U-0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:CVUGHM-C3V%UJ];WN>-_P#"5> M4U*TT_P?X-BUNZGD D5;01+$F>6)(_\
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# /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
